Cumberland Pharmaceuticals Inc (CPIX) Files Form 4 Insider Selling : Thomas R Lawrence Sells 3,000 Shares

Cumberland Pharmaceuticals Inc (CPIX): Thomas R Lawrence , director of Cumberland Pharmaceuticals Inc sold 3,000 shares on May 26, 2016. The Insider selling transaction was reported by the company on May 27, 2016 to the Securities and Exchange Commission. The shares were sold at $4.55 per share for a total value of $13,650.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 8, 2016, Thomas R Lawrence (director) sold 5,000 shares at $4.34 per share price.

Cumberland Pharmaceuticals: On Wednesday, May 25, 2016 heightened volatility was witnessed in Cumberland Pharmaceuticals which led to swings in the share price. The shares opened for trading at $4.6 and hit $4.6 on the upside , eventually ending the session at $4.55, with a gain of 0.89% or 0.04 points. The heightened volatility saw the trading volume jump to 14,589 shares. The 52-week high of the share price is $7.783 and the company has a market cap of $74 M . The 52-week low of the share price is at $4.2.

Cumberland Pharmaceuticals Money Flow Index Chart

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the acquisition development and commercialization of prescription products. Its target markets are hospital acute care and gastroenterology. It markets and sells its products through its hospital and gastroenterology sales forces in the United States. Its products include Acetadote Injection which is for the treatment of acetaminophen poisoning; Caldolor Injection which is used for the treatment of pain and fever; Kristalose is used for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and related duodenal ulcer disease; Vaprisol Injection to raise serum sodium levels in patients with euvolemic and hypervolemic hyponatremia; Hepatoren Injection for the treatment of ill patients suffering from liver and kidney failure and Boxaban oral capsules for the treatment of patients with aspirin-exacerbated respiratory disease.

Leave a Reply

Cumberland Pharmaceuticals - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cumberland Pharmaceuticals. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.